- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
- Interventions
- amifostine trihydrate, cisplatin, etoposide, radiation therapy
- Drug · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 4
- States / cities
- Denver, Colorado • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 14,759
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cystic Fibrosis
- Interventions
- Boost VHC, Ensure High Protein
- Dietary Supplement
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Cystic Fibrosis
- Interventions
- Docosahexanoic Acid Supplement, Placebo
- Dietary Supplement
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Respiratory Distress Syndrome, Adult
- Interventions
- Minimal (Trophic) Feeding, Full Feeding
- Behavioral
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 39
- States / cities
- Fresno, California • Sacramento, California • San Francisco, California + 19 more
- Conditions
- Asthma
- Interventions
- HFA-152a, HFA-134a
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 12
- States / cities
- Aventura, Florida • Miami, Florida • Naples, Florida + 7 more
- Conditions
- Peripheral Pulmonary Lesions (PPLs), Lung Nodules
- Interventions
- Bronchoscopy for peripheral pulmonary lesion biopsy
- Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Cleveland, Ohio
- Conditions
- Pulmonary Disease, Chronic Obstructive, Hypoxia
- Interventions
- Nocturnal Oxygen
- Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Asthma
- Interventions
- Placebo, Fluticasone
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 16 more
- Conditions
- Asthma in Children
- Interventions
- Bi-level Positive Airway Pressure, Sham Bi-level Positive Airway Pressure
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- DWN12088, Placebo
- Drug
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 20
- States / cities
- Mesa, Arizona • Phoenix, Arizona • San Francisco, California + 14 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- HyperAcute-Lung Cancer Vaccine
- Biological
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • St Louis, Missouri
- Conditions
- Asthma
- Interventions
- placebo, risankizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 20
- States / cities
- Costa Mesa, California • Mountain View, California • Centennial, Colorado + 16 more
- Conditions
- Connective Tissue Diseases
- Interventions
- Belimumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 4
- States / cities
- Los Angeles, California • New York, New York • Philadelphia, Pennsylvania
- Conditions
- Hypotension and Shock, Pulmonary Hypertension of the Newborn (PPHN), Hypoxemic Respiratory Failure
- Interventions
- Dopamine administration, Norepinephrine
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- Up to 28 Days
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Rhinitis, Allergic, Perennial, Asthma
- Interventions
- Glycerinated German Cockroach Allergenic Extract, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Chicago, Illinois • Baltimore, Maryland + 1 more
- Conditions
- Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
- Interventions
- JDQ443
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Human Papilloma Virus, Recurrent Respiratory Papillomatosis, Pulmonary Disease
- Interventions
- Lenvatinib, Pembrolizumab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Pneumovax (PPSV23), Prevnar (PCV7)
- Biological
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 181 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
- Conditions
- Cystic Fibrosis
- Interventions
- SB656933, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 14 more
- Conditions
- Cystic Fibrosis
- Interventions
- Essential amino acid intake + Leucine vs total AA supplement
- Dietary Supplement
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 2 Years to 99 Years
- Enrollment
- 1,310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 47
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • Long Beach, California + 41 more
- Conditions
- Lung Cancer
- Interventions
- Trastuzumab, Cisplatin, Gemcitabine Hydrochloride
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer, Mesothelioma, Suspected Lung Cancer, Suspected Mesothelioma
- Interventions
- Implantable Micro- drug delivery Microdevice (IMD)
- Drug
- Lead sponsor
- Oliver Jonas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts